PMID- 37043939
OWN - NLM
STAT- MEDLINE
DCOM- 20230509
LR  - 20230509
IS  - 1095-7103 (Electronic)
IS  - 0021-9797 (Linking)
VI  - 642
DP  - 2023 Jul 15
TI  - Microfluidic formulation of anticancer peptide loaded ZIF-8 nanoparticles for the 
      treatment of breast cancer.
PG  - 810-819
LID - S0021-9797(23)00540-4 [pii]
LID - 10.1016/j.jcis.2023.03.172 [doi]
AB  - Anticancer peptides (ACPs) are promising antitumor drugs owning to their great 
      cancer cell targeting and anticancer effects as well as low drug resistance. 
      However, many of the ACPs have non-specific toxicity and can be easily degraded 
      by the enzymes after administration. Therefore, drug delivery systems (DDSs) are 
      required to shield these peptides from degradation and induce targeted delivery. 
      In this paper, a high performance microfluidic device was used to fabricate the 
      zeolitic imidazolate framework (ZIF-8) encapsulating an ACP (At3) recently 
      developed by our group. The microfluidic device allowed for efficient and rapid 
      mixing to generate ACP loaded nanoparticles (NPs) with controllable properties at 
      high production rate (120 mL/min) and high encapsulation efficiency. The ZIF-8 
      NPs synthesised by microfluidic processing showed lower polydispersity index 
      (PDI) than the conventional method, demonstrating an improved size uniformity. 
      Encapsulating At3 into the ZIF-8 (At3@ZIF-8) significantly reduced the hemolytic 
      effect and provided a pH-controlled release of At3 peptide. At3@ZIF-8 showed 
      higher anticancer effect than the unloaded peptide at the same concentration due 
      to the enhanced cell uptake by the ZIF-8 NPs. The NPs were able to inhibit the 
      growth of the multicellular tumour spheroids (MCTSs) and damage the mitochondrial 
      membrane of the MCF-7 breast cancer cells. In vivo experiments demonstrated that 
      the At3@ZIF-8 NPs inhibited the growth of MCF-7 tumours in nude mice without 
      changing the biochemical properties of the blood or the histopathological 
      properties of vital organs. Therefore, the development of At3 loaded NPs provides 
      an alternative approach in ACP delivery which can broaden the application of 
      ACP-based cancer therapy.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Qiu, Jinguo
AU  - Qiu J
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
FAU - Tomeh, Mhd Anas
AU  - Tomeh MA
AD  - Department of Chemical and Biological Engineering, University of Shenfield, 
      Sheffield S1 3JD, UK.
FAU - Jin, Yi
AU  - Jin Y
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China; Department of 
      Pharmacy, Wujin People's Hospital, Changzhou 213000, China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
FAU - Zhao, Xiubo
AU  - Zhao X
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China; Department of 
      Chemical and Biological Engineering, University of Shenfield, Sheffield S1 3JD, 
      UK. Electronic address: xiubo.zhao@cczu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230330
PL  - United States
TA  - J Colloid Interface Sci
JT  - Journal of colloid and interface science
JID - 0043125
RN  - 1318-02-1 (Zeolites)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Zeolites/chemistry
MH  - Mice, Nude
MH  - Microfluidics
MH  - *Antineoplastic Agents/chemistry
MH  - *Nanoparticles/chemistry
MH  - Drug Delivery Systems
MH  - *Neoplasms/drug therapy
OTO - NOTNLM
OT  - Anticancer peptides
OT  - Cancer
OT  - Drug delivery
OT  - Microfluidics
OT  - Nanoparticles
OT  - ZIF-8
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/04/13 06:00
MHDA- 2023/05/09 06:42
CRDT- 2023/04/12 18:05
PHST- 2022/12/04 00:00 [received]
PHST- 2023/03/11 00:00 [revised]
PHST- 2023/03/27 00:00 [accepted]
PHST- 2023/05/09 06:42 [medline]
PHST- 2023/04/13 06:00 [pubmed]
PHST- 2023/04/12 18:05 [entrez]
AID - S0021-9797(23)00540-4 [pii]
AID - 10.1016/j.jcis.2023.03.172 [doi]
PST - ppublish
SO  - J Colloid Interface Sci. 2023 Jul 15;642:810-819. doi: 
      10.1016/j.jcis.2023.03.172. Epub 2023 Mar 30.